Dr. Mageto received her undergraduate degree in Health Sciences from Andrews University in Berrien Springs, Michigan and received her Medical Degree from Washington University in St. Louis, Missouri. She completed her Internal Medicine internship and residency at The University of Texas Southwestern Medical Center, Dallas. Dr. Mageto then went on to do her Pulmonary and Critical Care Fellowship at the University of Washington in Seattle where she also received her Masters of Public Health in Epidemiology.
Dr. Mageto has a primary focus and expertise in interstitial lung disease and runs a multidisciplinary interstitial lung disease clinic on a weekly basis with colleagues from other divisions. She also actively encourages fellows to see their interstitial lung disease patients in the clinic with faculty supervision. She is a clinician educator/researcher involved in multiple idiopathic pulmonary fibrosis trials and has also collaborated with investigators form other centers in sarcoidosis related lung disease. She is a PI on a number of IPF studies and is actively involved in the total care and management of these patients.
She also operates as a bio-informaticist for the hospital and is actively involved in working with the IT staff to improve the EHR for end users, thereby optimizing healthcare delivery, and improving patient care and access. One of her goals is to work to improve the EHR in this institution such that it becomes a useful clinical research tool as well as a healthcare delivery tome.American Thoracic Society
College of Chest PhysiciansSociety of Critical Care Medicine
Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, Abraham S, Mageto Y, Culver DA, Oswald-Richter KA, Drake WP. J Clin Immunol. 2013 Feb; 33(2): 446-55. doi: 10.1007/s10875-012-9817-6. Epub 2012 Oct 18.
Brown E, Stuard G, Liggin JD, Hukovic N, Frol A, Dhanani N, Khan DA, Larkin GL, McEwen BS, Rosenblatt, R, Mageto Y, Hanczyc M, Cullum M Effect of Phentoin on Mood and Declarative Memory During Prescription Corticosteroid Therapy. Biol Psy 2005; 47: 543-48.
Raghu G, Johnson WC, Lockhart D , Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, Pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999 Apr; 159(4pt1): 1061-9.
Raghu G, Mageto Y, Lockhart D., Schmidt R., Godwin J.D., Wood D.E. The Accuracy of the Clinical Diagnosis of New Onset Idiopathic Pulmonary Fibrosis and other interstitial lung disease: A prospective study. Chest 1999 Nov; 116(5): 1168-74.